Cargando…
The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
Tumor cells promote the suppression of host anti-tumor type 1 T cell responses by various mechanisms, including the upregulation of surface inhibitory molecules such as programmed death ligand (PD-L)-1, and the production of immunosuppressive cytokines such as interleukin-10 (IL-10). There are over...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620891/ https://www.ncbi.nlm.nih.gov/pubmed/34832887 http://dx.doi.org/10.3390/ph14111105 |
_version_ | 1784605327735390208 |
---|---|
author | Jimbu, Laura Mesaros, Oana Neaga, Alexandra Nanut, Ana Maria Tomuleasa, Ciprian Dima, Delia Bocsan, Corina Zdrenghea, Mihnea |
author_facet | Jimbu, Laura Mesaros, Oana Neaga, Alexandra Nanut, Ana Maria Tomuleasa, Ciprian Dima, Delia Bocsan, Corina Zdrenghea, Mihnea |
author_sort | Jimbu, Laura |
collection | PubMed |
description | Tumor cells promote the suppression of host anti-tumor type 1 T cell responses by various mechanisms, including the upregulation of surface inhibitory molecules such as programmed death ligand (PD-L)-1, and the production of immunosuppressive cytokines such as interleukin-10 (IL-10). There are over 2000 trials investigating PD-L1 and/or its receptor programmed-death 1 (PD-1) blockade in cancer, leading to the approval of PD-1 or PD-L1 inhibitors in several types of solid cancers and in hematological malignancies. The available data suggest that the molecule PD-L1 on antigen-presenting cells suppresses type 1 T cell immune responses such as cytotoxicity, and that the cytokine IL-10, in addition to downregulating immune responses, increases the expression of inhibitory molecule PD-L1. We hypothesize that the manipulation of both the co-inhibitory network (with anti-PD-L1 blocking antibodies) and suppressor network (with anti-IL-10 blocking antibodies) is an attractive immunotherapeutic intervention for acute myeloid leukemia (AML) patients ineligible for standard treatment with chemotherapy and hematopoietic stem cell transplantation, and with less severe adverse reactions. The proposed combination of these two immunotherapies represents a new approach that can be readily translated into the clinic to improve the therapeutic efficacy of AML disease treatment. |
format | Online Article Text |
id | pubmed-8620891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86208912021-11-27 The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia Jimbu, Laura Mesaros, Oana Neaga, Alexandra Nanut, Ana Maria Tomuleasa, Ciprian Dima, Delia Bocsan, Corina Zdrenghea, Mihnea Pharmaceuticals (Basel) Review Tumor cells promote the suppression of host anti-tumor type 1 T cell responses by various mechanisms, including the upregulation of surface inhibitory molecules such as programmed death ligand (PD-L)-1, and the production of immunosuppressive cytokines such as interleukin-10 (IL-10). There are over 2000 trials investigating PD-L1 and/or its receptor programmed-death 1 (PD-1) blockade in cancer, leading to the approval of PD-1 or PD-L1 inhibitors in several types of solid cancers and in hematological malignancies. The available data suggest that the molecule PD-L1 on antigen-presenting cells suppresses type 1 T cell immune responses such as cytotoxicity, and that the cytokine IL-10, in addition to downregulating immune responses, increases the expression of inhibitory molecule PD-L1. We hypothesize that the manipulation of both the co-inhibitory network (with anti-PD-L1 blocking antibodies) and suppressor network (with anti-IL-10 blocking antibodies) is an attractive immunotherapeutic intervention for acute myeloid leukemia (AML) patients ineligible for standard treatment with chemotherapy and hematopoietic stem cell transplantation, and with less severe adverse reactions. The proposed combination of these two immunotherapies represents a new approach that can be readily translated into the clinic to improve the therapeutic efficacy of AML disease treatment. MDPI 2021-10-29 /pmc/articles/PMC8620891/ /pubmed/34832887 http://dx.doi.org/10.3390/ph14111105 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Jimbu, Laura Mesaros, Oana Neaga, Alexandra Nanut, Ana Maria Tomuleasa, Ciprian Dima, Delia Bocsan, Corina Zdrenghea, Mihnea The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia |
title | The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia |
title_full | The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia |
title_fullStr | The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia |
title_full_unstemmed | The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia |
title_short | The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia |
title_sort | potential advantage of targeting both pd-l1/pd-l2/pd-1 and il-10–il-10r pathways in acute myeloid leukemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620891/ https://www.ncbi.nlm.nih.gov/pubmed/34832887 http://dx.doi.org/10.3390/ph14111105 |
work_keys_str_mv | AT jimbulaura thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT mesarosoana thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT neagaalexandra thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT nanutanamaria thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT tomuleasaciprian thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT dimadelia thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT bocsancorina thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT zdrengheamihnea thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT jimbulaura potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT mesarosoana potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT neagaalexandra potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT nanutanamaria potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT tomuleasaciprian potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT dimadelia potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT bocsancorina potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT zdrengheamihnea potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia |